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Objectives: Diagnosis and monitoring of lymphoma includes lymph node assess-
ment. This study examined the association of multiple lymph node biopsies and 
health care resource use among lymphoma patients. MethOds: Patients with ≥ 2 
claims for Hodgkin lymphoma (HL) or non-Hodgkin’s (NHL) lymphoma from 1/1/06-
12/31/12 were identified from a large US claims database; the index date was the 
first lymphoma claim date. Patients were retained if continuously enrolled in the 
health plan for ≥ 12 months before and after the index date, were not diagnosed 
with lymphoma during the pre-index period or diagnosed with cancer other than 
lymphoma. Health care cost and utilization were examined during the 2-year study 
period. Indication of receipt of biopsy included ≥ 1 claim for a lymph node biopsy 
(core needle, fine needle, surgical, other), pathology, or tumor excision (bone marrow 
biopsy not included). Health care cost and utilization was examined among patients 
with 0 to ≥ 3 biopsies. The cost of claims indicating biopsy was identified for each 
biopsy type. Results: 20,813 newly diagnosed lymphoma patients met all inclu-
sion criteria. 16,557 (80%) had ≥ 1 claim indicating biopsy, 12,920 (62%) had ≥ 2 and 
8,783 (42%) had ≥ 3. The percentage with an inpatient stay and ER visit was greatest 
among patients with ≥ 3 biopsies (52%, 53%) compared to patients with 2 (33%, 41%), 
1 (25%, 34%), or 0 biopsies (26%, 42%). Total health care cost was greatest among 
patients with ≥ 3 biopsies ($102,465) compared to 2 ($51,565), 1 ($25,614), or 0 biopsies 
($15,671). The cost of biopsies ranged from $307 for a fine needle biopsy to $3,296 
for a complex surgical biopsy and $12,353 for other biopsies. Biopsies involving the 
mediastinum cost $10,554 on average. cOnclusiOns: Lymphoma patients incur 
significant health care cost and utilization. Increasing the efficiency of lymph node 
diagnosis could avoid the need for repeat biopsies and reduce health care costs.
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Objectives: To measure the costs of two team-care based pilot interventions. These 
interventions are part of the Chicago-based National Institutes of Health-funded 
Centers for Population Health and Health Disparities (CPHHD) designed to improve 
health outcomes in medically underserved communities. MethOds: The data 
come from two Chicago-based CPHHD randomized controlled trials. Use of a vir-
tual team aimed at reducing depressive symptoms in older adults with depression 
(BRIGHTEN Heart) and cardio-metabolic syndrome and use of a patient navigator 
to improve diagnostic follow-up of mammography screening for breast cancer. The 
programs collected detailed data regarding service delivery and resource use. Costs 
were measured from a provider perspective. Actual time spent with patients was 
estimated in the navigator program using details on activities performed and previ-
ous time study data for those activities in similar programs. Time was converted 
to costs based on average wages reported by the Bureau of Labor Statistics (BLS) 
by occupational title. BRIGHTEN Heart involved multiple services along with time 
and travel cost estimates for each occupation and service. Results: There were 
493 patients that received patient navigator services and 16 patients in the virtual 
team-based BRIGHTEN Heart intervention. The patients were almost all minorities 
and were below average in terms of income and education. The operating cost of the 
Navigator program was $14.29 following diagnostic screening. The operating cost 
for the year of virtual team care in BRIGHTEN Heart was $753.18. cOnclusiOns: 
Costs are an important consideration for evaluating team-care based interventions 
to improve patient health in the underserved. The two programs evaluated here 
offer insight into the relatively low cost of interventions with team-care strategies 
employing allied health workers. Given the low cost of care, the programs offer 
promise of being cost effective. Future work will examine these costs in comparison 
to the effectiveness of the program.
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Objectives: To examine patient characteristics, treatment patterns, and health 
care resource utilization of patients with neuroendocrine tumors (NETs) in the 
US. MethOds: Using a US administrative claims database, commercially-insured 
adults newly diagnosed with carcinoid tumors (ICD-9-CM: 209.xx) or pancreatic 
islet cell tumors (ICD-9-CM: 157.4 and 211.7) between 07/01/2007 and 12/31/2010 
were identified (the date of the first observed diagnosis as the index date). Patients 
were required to have 6-month pre-index and 12-month post-index continuous 
enrollment. Descriptive analysis was performed to describe demographic and clini-
cal characteristics, treatment patterns for NETs, and health care resource utiliza-
tion during the 12-month post-index period. Similar analysis was conducted for 
Medicare-eligible individuals with the supplemental private insurance. Results: 
This study included 3,940 commercially-insured individuals (mean age: 52.3 years; 
55.4% female) and 1,658 Medicare-eligible individuals (mean age: 74.9 years; 49.0% 
female) with NETs. In the commercial population, carcinoid syndrome (33.2%), liver 
metastasis (22.4%), and nausea/vomiting (18.2%) were most common among the 
comorbidities evaluated. While 19.5% of individuals received surgical therapy and 
17.5% received medical therapy (somatostatin analogue treatment) as the first-
line treatment, nearly two-thirds received neither of those treatments. During the 
12-month post-index period, about half of individuals had inpatient hospitalization 
and 35.4% had emergency room visits; the mean physician office visit was 19.9. 
In the Medicare population, carcinoid syndrome (27.4%), liver metastasis (20.7%), 
and diarrhea (16.1%) were the most prevalent comorbidities. While 13.2% received 
surgical therapy and 19.8% received medical therapy, over two-thirds received nei-
ther. Approximately half of individuals had inpatient hospitalization and 37.3% had 
emergency room visit during the 12-month post-index period; the mean physician 
office visit was 26.1. cOnclusiOns: This exploratory study described real world 
Based Measure-SBM) and Malmquist index with Clearances. The sum of these two 
items is corresponding to the total expenditure in the sector analysed. Output: the 
output is defined as the number of renal transplants performed by every Brazilian 
State. Results: Examining the decomposition of the Malmquist index, has that 
18 States increased the index of pure change of efficiency (Pairing) with values 
greater than 1. According to the results, 21 States have submitted an index less 
than 1, indicating an offset of the boundary of production to a lower level. The 
analysis of efficiency of Brazilian States proposed in this study indicates a need 
for a better allocation and/or application of the resources spent by the SUS in the 
area of kidney transplants. cOnclusiOns: The results of this survey suggest that 
the process of kidney transplants has presented an activity with great variability 
between States. The offer of the kidney organ becomes insufficient in these places 
to meet the demand, creating queues of waiting for a kidney transplant. The sys-
tem of kidney transplants in Brazil, in the current period, presents a number of 
surgeries that are below the population’s needs, due mainly to the lack of effective 
donations of this organ.
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Objectives: TSC is a multi-system genetic disorder that affects up to 8,000 patients 
in the UK. It is associated with non-malignant lesions throughout the body, neu-
rological manifestations, and impaired cognition. Consequently, the burden on 
patients, their families, and the health care system is thought to be substantial. 
This study assesses the real-world economic impact of TSC in the UK. MethOds: 
TSC patients were retrospectively identified between April, 1997 to March, 2012 in 
CPRD (Read: PK5.00, PK5.12) and linked Hospital Episodes Statistics (HES; ICD-10: 
Q85.1) databases. Health care encounters in the following settings were analysed: 
general practitioner (GP), inpatient, emergency room (ER) admissions and outpa-
tient. Analyses were stratified by age at time of occurrence for pediatrics (< 18 years) 
and adults (≥ 18 years). Results: A total of 341 TSC patients were identified (52% 
female; median age 14.4 years at first event). The annual rate (mean[SD]) of health 
care encounters (by person-year) was 13.7(14.3) for paediatrics and 15.6(15.3) for 
adults. Annual rates (mean[SD]) of paediatric vs. adult encounters by care setting 
was as follows: GP, 10.1(3.1) vs. 12.9(14.2); inpatient, 1.0(1.6) vs. 0.6(1.0); ER admis-
sion, 0.4(0.8) vs. 0.3(0.7); outpatient, 3.9(3.3) vs. 2.8(3.0). Neurological manifestations 
(primarily epilepsy, including infantile spasms and status eptilepticus) were most 
common in pediatrics resulting in inpatient and ER admission use in 53% and 62% 
of patients, respectively. Musculoskeletal manifestations were most common in 
adults resulting in inpatient and ER use in 31% and 33% of patients, respectively. 
Mean(SD) number of surgical procedures and tests/patient-year was 0.2(0.4) and 
0.3(0.4), respectively. MRI or CT scans were observed in 34% of pediatrics and 26% 
of adults. cOnclusiOns: Health care resource utilization rates suggest significant 
economic burden of TSC throughout life. Absence of MRI or CT procedures may 
signify deviation from recommended monitoring guidelines. Further analyses will 
quantify the cost impact of TSC on the UK health care system.
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Objectives: The aim of this study was to identify high cost sickle cell disease (SCD) 
patients (HCSPs) and analyze their cost patterns throughout lifetime and as they 
transition from pediatric to adult care. MethOds: State Medicaid data from 1997 to 
2010 were analyzed. Patients with ≥ 2 SCD diagnoses and ≥ 1 blood transfusion were 
included. HCSPs were defined as the fraction of most expensive patients account-
ing for 50% of the total yearly costs. Periodic events associated with high costs are 
likely to be responsible for high total costs. High cost events (HCEs), defined as quar-
ters with costs ≥ $33,095, corresponding to the amount separating the top 5% most 
expensive quarters observed in the sample, were analyzed. A longitudinal logistic 
regression model was used to identify factors associated with HCEs. Results: 
From a cohort of 3,208 eligible SCD patients, 449 (14%) were identified as HCSPs. 
The average yearly total cost of HCSPs was significantly higher at $108,524/year 
compared to $17,683/year for other patients. The share of the total yearly costs of 
HCSPs increased from 34.4% to 46.3% between age groups 11-15 and 16-20, reaching 
its maximum at 65.2% in the 26-30 age group. The frequency of HCEs increased by 
122.6% in the transitioning group from 0.110 HCE/year among patients aged 11-15 to 
0.244 HCE/year among patients aged 16-20. Patients were more likely to have a HCE 
during the post-transition period (adjusted odds ratio [OR]: 1.41, p= .0046) and when 
experiencing an SCD complication (OR: 3.79, p< .0001). Blood transfusions received 
during the previous quarter were associated with a lower likelihood of HCEs (OR: 
0.87, p= .0080). cOnclusiOns: In this population of Medicaid SCD patients, 14% 
were responsible for over 50% of total yearly health care costs. Directing appropriate 
and targeted interventions can help assist providers improve outcomes and lower 
health care costs in this patient population.
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mammography cancer preventive services, veterans are less likely to have had a 
mammogram in the past year controlling for a wide range of socio-demographic 
variables. There is no significant difference in women veterans and women non-vet-
erans and their utilization of pap smears in the 2011 data. cOnclusiOns: Despite 
documented evidence in early cancer detection, take up rates for mammography 
and colonoscopy among US veterans appears lower than non veterans. Veterans may 
not be accessing the prevention services available to them in the VA and perhaps 
awareness and education can increase these rates in the future.
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Objectives: To analyze cost savings for the first year of a rheumatoid arthritis 
(RA) pathway program. Cardinal Health collaborated with CareFirst BlueCross 
BlueShield to develop the first payer-sponsored RA pathway program in the 
United States. Private-practice rheumatologist participation was voluntary, but 
reimbursement enhancements were offered to mitigate cost of pathway adoption 
and compliance. A steering committee comprised of 12 participating physicians 
created the pathway, which included an obligatory use of a real-time decision 
support and data capture tool; use of disease-modifying antirheumatic drugs 
(DMARDs) as first-line treatment for at least 12 weeks prior to use of biologic 
agents; and a requirement that dose, schedule, and adjustments for biologic agents 
follow package label prescribing guidelines. MethOds: 80 physicians in 37 prac-
tices participated in the program; 876 active treatment patients were accrued 
from 2/1/12-1/31/12. Claims data augmented and validated tool-data capture. A 
first month to last month trend design was used to calculate savings regarding 
the percentage of patients initially treated with DMARDs and the use of biologic 
agents by label dose and schedule. A matched control design was used to asses 
savings for site of care based on the percentage of patients who received office-
based versus hospital-based infusions among participating and nonparticipating 
community rheumatologists. Results: DMARD use increased by 7.4% over the 
first year contributing to a lower cost of care annualized at $1,069,790. Control 
of biologic “dose-creep” contributed $80,230 to further lowering cost annually. 
Average hospital facility costs per biologic infusion were near double that of 
community practice ($5000 vs $2500, respectively). Participating providers had 
80% fewer facility infusions than nonparticipating providers (11% vs 55%, respec-
tively). cOnclusiOns: RA pathway algorithm-compliant prescribing behavior for 
DMARDs and biologics resulted in dramatic savings. Preserving community site of 
care represents a significant savings potential for RA management.
HealtH ServiCeS – Patient-reported outcomes & Patient Preference Studies
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Objectives: Previous studies that have evaluated the association between mam-
mography screening and stage at breast cancer (BC) diagnosis had limitations 
because they did not analyze persistence to mammography screening and did not 
distinguish screening from diagnostic mammograms. The primary objective of this 
study is to determine the association between persistence to mammography screen-
ing and stage at BC diagnosis among elderly women. MethOds: A retrospective 
cohort study was conducted using Surveillance, Epidemiology, End Results (SEER)-
Medicare database. The study population consisted of elderly women age > 70 diag-
nosed with incident BC in 2007 (N = 7,945). Persistence to mammography screening 
was measured as having at least three mammograms during the 5 years prior to BC 
diagnosis. A validated algorithm with very high sensitivity and specificity was used 
to distinguish between screening and diagnostic mammograms. Chi-square tests 
and multinomial logistic regressions were performed to analyze the association 
between persistence to mammography screening and stage of BC diagnosis, after 
controlling for predisposing, enabling, need, health care use, and external environ-
ment factors. Results: Overall, 45.4% of elderly women with incident BC were 
persistent to annual or biennial screening mammograms, 26.4% were not persistent 
to annual or biennial screening mammograms and 28.2% did not have any mam-
mogram. As compared to women who did not have any mammogram, women who 
were persistent to screening mammography were significantly more likely to be 
diagnosed at earlier stages. The adjusted odds ratios were: 44.96 (95%CI= 31.3-64.4), 
10.90 (95%CI= 8.1-14.6), and 3.40 (95%CI= 2.5-4.6) for insitu, local, and regional stages, 
respectively. cOnclusiOns: Only a minority of elderly women were persistent 
to annual or biennial screening mammograms and persistence to mammography 
screening was associated with earlier BC disease stage. Interventions designed to 
promote persistent screening mammograms among elderly women are warranted.
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Objectives: Patients new to therapy for chronic conditions often have poor medi-
cation adherence that can lead to adverse outcomes and higher medical costs. 
Previous studies have demonstrated the benefit of pharmacist interventions to 
improve adherence. The objective of this study is to evaluate the impact of a commu-
nity pharmacist telephone call program on medication adherence in patients new 
treatment patterns of patients with NETs, and future research should investigate 
the management strategy of different symptoms in this population and its impact 
on health care resource utilization and costs.
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Objectives: This study of hospitalized Medicare beneficiaries with acute bacterial 
skin and skin structure infections (ABSSSI) diagnoses describes inpatient hospital 
cost and resource use by patients with primary ABSSSI infections. MethOds: The 
study used Medicare Provider Analysis and Review (MedPAR) Files from 2011—2012 
containing claims for 313,646 patients in 2011 and 317,527 patients in 2012 with 
a primary ABSSSI diagnosis with Age ≥ 18 from a 100% sample of hospitalized 
Medicare beneficiaries during 2011-2012. Reimbursements were derived from 2012 
MedPAR data and costs were derived from 2010 Premier data, inflated (4.7%) to 2012 
using the October 2013 hospital producer price index (PPI) generated by the Bureau 
of Labor Statistics. Net reimbursement was analyzed by MS-DRG and LOS. The analy-
sis used regression modeling to determine factors correlated with LOS. Results: 
Median Charlson Comorbidity Index (CCI) was 3; patients tended to have more cel-
lulitis on the trunk, foot, and toe. The median LOS was three days. Sixteen percent 
of patients used the ICU/CCU. For MS-DRG 603 (Cellulitis without MCC), the most 
common MS-DRG comprising 61% of admissions, net reimbursement was positive 
when LOS ≤ 3 days, but 52% of admissions were projected to result in financial losses 
to the hospital. Age, non-minority status, Northeast census region, CCI, cellulitis on 
the leg and traumatic wound infection were correlated with longer LOS; diagnoses 
of erysipelas, diabetes without complications and drug abuse were correlated with 
shorter LOS. Median costs were $5,612. cOnclusiOns: The median length of stay 
for Medicare patients is shorter than the indicated length of antibiotic drug treat-
ment for ABSSSI (7-10 days), implying that most patients complete treatment in 
ambulatory settings. Hospitalization cost is projected to be less than reimbursement 
for many of the most common type of ABSSSI patients.
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Objectives: Residential services costs have been associated with multiple variables 
such as resident psychiatric status and severity of symptoms, daily living skills, 
social behaviour problems, geographic region, service size, gender and age. In 2008, 
up to twenty full staffed homes were created in Sao Paulo city, in order to accommo-
date people discharged from psychiatric hospitals. Aims of this study were to esti-
mate the direct costs of staffed homes and also to explore the relationship between 
resident profile and services costs. MethOds: We used a bottom-up approach for 
the estimation of direct costs according to public health service provider perspective. 
Direct costs included costs with accommodation, inpatient, outpatient and emer-
gency health services and treatment received in the previous month, in 147 subjects 
with mental disorders living in twenty full staffed homes during the year 2011. We 
evaluated resident profile (quality of life, social behaviour problems, psychiatric 
diagnosis, severity of symptoms, socio demographic characteristics) and pattern of 
health service use. Linear regression analysis was employed to verify the effect of 
resident profile on residential services costs. Results: Residential services costs 
corresponded to 89% of the total direct costs including accommodation, health care 
and medication, and of these, 62% were due to human resources costs, 8% to trans-
portation and house repairs and 7% to overhead. Residential costs were associated 
exclusively with geographic region, length of time living in psychiatric hospital and 
length of time living in residential service. Mean of residential costs per month per 
capita was U$1,750.00 (1U$= 2.00 R$-Brazilian currency). One-fourth to one-third 
of the sample presented good scores of autonomy, social behaviour and psychiatric 
status. cOnclusiOns: Direct costs of residential services could be optimized if 
one-fourth of sample with good autonomy and appropriate social behaviour would 
be transferred to less expensive services like semi-staffed or not staffed homes.
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bAckgROund:: The utilization of cancer preventive care services including 
mammography, colonoscopy and pap smears in the United States remains low, 
despite their established success in reducing cancer deaths. Due to the harmful 
exposures during their service years veterans may have more negative health 
outcomes compared to nonveterans. The rising costs of cancer treatment and a 
focus on quality treatment require the public to understand how VA resources are 
being used and if they are providing high quality and effective care to our nations’ 
Veterans. Objectives: To understand the difference in the utilization of preven-
tive services (specifically mammography, colonoscopy and pap smears) in the US 
between veterans and non veterans. Veterans have reported reasons for declining 
preventive services like previous negative results, no time to get tested, no risk 
factors, getting testing not being a priority, uninterested in knowing, and already 
infected. This paper assesses the difference in the utilization of preventive services 
with data from the Household Component (HC) of the Medical Expenditure Panel 
Survey (MEPS) from 2011. MethOds: We attempted to understand the differences 
in utilization of cancer related preventative services between veterans and non-
veterans in 2011 using regression analyses. Results: For both colonoscopy and 
